AFP and hepatocellular carcinoma: As shown in Figure S2, the decision curve analysis indicated that when the threshold probabilities ranged between about 0.5% and 80% in each cohort, the use of the “AGTAG” model to HCC risk provided greater net benefit than the “treat all,” “treat none,” or “AFP” strategies, which indicates the clinical usefulness of the “AGTAG” model.